HC Wainwright Increases Soleno Therapeutics (NASDAQ:SLNO) Price Target to $100.00

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) had its price objective raised by equities researchers at HC Wainwright from $70.00 to $100.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's target price points to a potential upside of 45.39% from the stock's previous close. HC Wainwright also issued estimates for Soleno Therapeutics' Q1 2025 earnings at ($0.80) EPS, Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.76) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at $0.16 EPS, Q3 2026 earnings at $0.37 EPS, Q4 2026 earnings at $1.06 EPS and FY2026 earnings at $1.39 EPS.

Several other equities research analysts have also commented on SLNO. Lifesci Capital raised shares of Soleno Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 4th. Guggenheim reissued a "buy" rating and issued a $81.00 price target (up from $70.00) on shares of Soleno Therapeutics in a research report on Friday, March 28th. Robert W. Baird upped their price target on Soleno Therapeutics from $72.00 to $102.00 and gave the stock an "outperform" rating in a research note on Thursday, March 27th. Stifel Nicolaus lifted their price objective on Soleno Therapeutics from $74.00 to $108.00 and gave the company a "buy" rating in a research note on Friday, March 28th. Finally, Laidlaw increased their target price on Soleno Therapeutics from $75.00 to $105.00 and gave the stock a "buy" rating in a research note on Thursday, March 27th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $99.63.

Soleno Therapeutics Trading Down 4.7 %

Soleno Therapeutics stock traded down $3.38 during trading hours on Monday, hitting $68.78. 556,234 shares of the stock traded hands, compared to its average volume of 666,135. Soleno Therapeutics has a one year low of $36.61 and a one year high of $74.00. The company has a market cap of $3.15 billion, a PE ratio of -20.72 and a beta of -2.29. The firm's 50-day moving average price is $50.80 and its two-hundred day moving average price is $50.65.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.41). On average, sell-side analysts expect that Soleno Therapeutics will post -3.72 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Bhatnagar Anish sold 699,095 shares of the firm's stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $67.62, for a total value of $47,272,803.90. Following the sale, the chief executive officer now owns 577,076 shares in the company, valued at approximately $39,021,879.12. This trade represents a 54.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Patricia C. Hirano sold 128,653 shares of the business's stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $68.32, for a total transaction of $8,789,572.96. Following the sale, the insider now owns 55,789 shares of the company's stock, valued at approximately $3,811,504.48. This represents a 69.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 942,672 shares of company stock valued at $64,058,781 in the last 90 days. 12.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Soleno Therapeutics

Large investors have recently made changes to their positions in the company. Janus Henderson Group PLC boosted its holdings in shares of Soleno Therapeutics by 27.1% in the fourth quarter. Janus Henderson Group PLC now owns 5,188,265 shares of the company's stock worth $233,130,000 after buying an additional 1,107,166 shares during the last quarter. Nantahala Capital Management LLC boosted its stake in shares of Soleno Therapeutics by 20.1% during the 4th quarter. Nantahala Capital Management LLC now owns 3,928,966 shares of the company's stock worth $176,607,000 after acquiring an additional 658,518 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of Soleno Therapeutics by 15.8% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,525,000 shares of the company's stock worth $113,499,000 after acquiring an additional 344,000 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Soleno Therapeutics by 19.2% during the 4th quarter. Vanguard Group Inc. now owns 1,884,533 shares of the company's stock valued at $84,710,000 after acquiring an additional 303,806 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Soleno Therapeutics by 24.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,630,718 shares of the company's stock worth $73,301,000 after purchasing an additional 321,223 shares in the last quarter. 97.42% of the stock is currently owned by institutional investors.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.